Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Cofoe Medical, indicating a decline in revenue and profit in the latest quarterly report while comparing its valuation metrics to industry averages [1][2][3] Group 2 - Cofoe Medical's stock closed at 42.0 yuan, down 1.50%, with a rolling PE ratio of 29.08 times and a total market capitalization of 8.782 billion yuan [1] - The average PE ratio for the medical device industry is 59.32 times, with a median of 39.97 times, placing Cofoe Medical at the 56th position in the industry ranking [1][3] - As of the first quarter of 2025, five institutions held shares in Cofoe Medical, with a total of 6.344 million shares valued at 211 million yuan [1] - Cofoe Medical specializes in the research, production, sales, and service of medical devices, with a diverse product range including blood glucose systems, blood pressure monitors, and various medical supplies [2] - The latest quarterly report for Q1 2025 shows Cofoe Medical achieved revenue of 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of 91.425 million yuan, down 9.68%, with a gross profit margin of 52.17% [2]
可孚医疗收盘下跌1.50%，滚动市盈率29.08倍，总市值87.82亿元